Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Wyeth has purchased a non-exclusive license to use Xoma's bacterial expression technology for the development and production of new proteins for therapeutic purposes.
Subscribe to our email newsletter
Bacterial cell expression technology (BCE) is used to discover and screen, as well as develop and manufacture, recombinant proteins and antibodies.
Currently there are two antibody products in late-stage clinical testing that are manufactured using Xoma’s BCE technologies. These are Celltech Group’s Cimzia, in development for rheumatoid arthritis and Crohn’s disease, and Genentech’s antibody Lucentis, for wet age-related macular degeneration (AMD).
“We are pleased that Wyeth has licensed Xoma’s bacterial expression technology for future development opportunities and anticipate a very positive relationship between the companies,” said John Castello, Xoma’s chairman, president and chief executive officer.
Details of the initial payment and future contingent payments to Xoma’s were not disclosed.